April 9 (Reuters) – C4 Therapeutics said on Thursday it has entered into a deal focused on research and development of a type of cancer drug with Swiss drugmaker Roche that could be worth more than $1 billion. * The companies will collaborate on two programs to developdegrader-antibody conjugates against undisclosed oncologytargets exclusive to the […]
Health
C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion
Audio By Carbonatix
April 9 (Reuters) – C4 Therapeutics said on Thursday it has entered into a deal focused on research and development of a type of cancer drug with Swiss drugmaker Roche that could be worth more than $1 billion.
* The companies will collaborate on two programs to developdegrader-antibody conjugates against undisclosed oncologytargets exclusive to the agreement. * Degrader-antibody conjugates (DAC) are an emerging classof cancer therapies that combine antibody-drug conjugation withtargeted protein degradation technology. * Roche will be responsible for advancing DAC candidatesthrough preclinical and clinical development as well ascommercialization. * C4T will receive a $20 million upfront payment for the twoprograms. If Roche exercises its option for a third target, C4Twill receive an additional payment. * C4T is also eligible to receive over $1 billion indiscovery, regulatory and commercial milestone payments, andentitled to tiered royalties on future sales. * The agreement marks the third collaboration between thetwo companies and extends a relationship that began in 2016.
(Reporting by Kunal Das in Bengaluru; Editing by Mrigank Dhaniwala)